A meta-analysis to compare the prevalences of endocrine dysfunctions with different immunotherapy regimens involving 19,922 patients found that the incidence of hypothyroidism was higher in patients treated with anti–PD-1 monotherapy (nearly 5–8.0%) than in patients treated with ipilimumab monotherapy (3.8%) (de Filette et al., 2019). Here, RPL17 is linked to hypothyroidism.